RxDoctor Payments Data

Jennifer Difalco, MD

Family Medicine · Brockton, MANPI 1558636373

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.5% of the total across 500 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,382in general payments, 2019–2025

Across 500 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Lilly USA, LLC$915
  • Tosoh Bioscience, Inc.$558
  • Novartis$463
  • Novo Nordisk$441
  • plus $5K from 50 others

What the payments were for

  • Consulting fees$501%
  • Food & beverage$8,77494%
  • Gifts$5586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)71$1,298
Pfizer67$1,079
Lilly USA, LLC44$915
Tosoh Bioscience, Inc.1$558
Novartis39$463
Novo Nordisk23$441
Merck20$354
Amgen18$315
Biohaven Pharmaceuticals, Inc.14$270
Antares Pharma, Inc.13$244
AstraZeneca(2 entities)10$224
Eisai Inc.14$197
Exact Sciences8$189
Esperion Therapeutics, Inc.12$185
Shield Therapeutics Inc9$178
GSK9$167
Amarin Pharma, Inc.8$150
Kowa Pharmaceuticals America, Inc.9$150
Boehringer Ingelheim7$144
Abbott9$135
Johnson & Johnson8$131
Sanofi Pasteur Inc.6$119
Therapeuticsmd, Inc.7$110
E.r. Squibb & Sons, L.L.C.5$91
Idorsia Pharmaceuticals US Inc5$83
Mayne Pharma Commercial LLC4$82
Axsome Therapeutics, Inc.4$79
Takeda Pharmaceuticals U.S.A., Inc.5$75
Astellas Pharma US Inc3$68
Vanda Pharmaceuticals Inc.3$68
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$63
Teva Pharmaceuticals USA, Inc.4$61
Medicines3601$50
Amneal Pharmaceuticals LLC2$48
IBSA Pharma Inc.3$46
Edwards Lifesciences1$44
Acerus Pharmaceuticals Corporation3$44
Tolmar, Inc.3$43
Seqirus USA Inc2$41
Hologic Sales And Service, LLC2$40
Otsuka America Pharmaceutical, Inc.2$38
Lucid Diagnostics Inc.2$29
Biohaven Pharmaceutical Holding Company Ltd.2$29
ANI Pharmaceuticals, Inc.1$29
Scilex Pharmaceuticals Inc.2$26
Hikma Pharmaceuticals USA2$26
Phathom Pharmaceuticals, Inc.1$21
Halozyme Inc1$21
Tersera Therapeutics LLC1$20
Sanofi-aventis U.S. LLC1$18
Paratek Pharmaceuticals, Inc.1$18
Endo Pharmaceuticals Inc.1$16
Boston Scientific1$16
Avanir Pharmaceuticals, Inc.1$14
Xeris Pharmaceuticals, Inc.1$13
Genentech USA, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,382 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$51,400
Medicare patients
184
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan20$16,841
EliquisApixaban21$14,126
OzempicSemaglutide16$13,732
Xtampza ErOxycodone Myristate12$8,334
Estradiol (Twice Weekly)Estradiol18$2,046
Atorvastatin Calcium156$1,802
Rosuvastatin Calcium41$1,508
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide11$1,172
Albuterol Sulfate HfaAlbuterol Sulfate32$941
Metoprolol Succinate33$848
Omeprazole40$778
Hydrocortisone17$744
Levetiracetam17$626
Levothyroxine Sodium66$618
Amlodipine Besylate45$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$463$16,84120 claims
PfizerEliquis$1,079$14,12621 claims
Novo NordiskOzempic$441$13,73216 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$48$61866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →